Angion Biomedica Corp. (ANGN)

NASDAQ: ANGN · IEX Real-Time Price · USD
2.32
-0.13 (-5.31%)
At close: Jan 14, 2022 4:00 PM
2.35
0.03 (1.29%)
After-hours:Jan 14, 2022 7:16 PM EST
Market Cap69.50M
Revenue (ttm)2.83M
Net Income (ttm)-98.34M
Shares Out29.96M
EPS (ttm)-4.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume108,131
Open2.40
Previous Close2.45
Day's Range2.25 - 2.51
52-Week Range2.25 - 26.30
Betan/a
AnalystsStrong Buy
Price Target21.00 (+805.2%)
Earnings DateNov 11, 2021

About ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synt...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees72
Stock ExchangeNASDAQ
Ticker SymbolANGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ANGN stock is "Strong Buy." The 12-month stock price forecast is 21.00, which is an increase of 805.17% from the latest price.

Price Target
$21.00
(805.17% upside)
Analyst Consensus: Strong Buy

News

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases

1 week ago - GlobeNewsWire

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

Angion's (ANGN) phase II study evaluating ANG-3777 in cardiac surgery-associated acute kidney injury fails to achieve the primary endpoint.

1 month ago - Zacks Investment Research

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated ac...

ST. GALLEN, Switzerland & UNIONDALE, N.Y.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results fro...

1 month ago - Business Wire

Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acu...

-- Angion to host a conference call today at 4:30 p.m. EST

1 month ago - GlobeNewsWire

Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Ended the quarter with nearly $103M in cash and cash equivalents Ended the quarter with nearly $103M in cash and cash equivalents

2 months ago - GlobeNewsWire

Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming P...

UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

2 months ago - GlobeNewsWire

Angion to Participate in Upcoming Investment Conference

UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

2 months ago - GlobeNewsWire

Why Did Angion Biomedica's Shares tumble Premarket Today?

After flopping a test in COVID-19 earlier this year, Angion Biomedica Corp's (NASDAQ: ANGN) lead candidate drug has hit a setback again, this time in kidney transplant patients. Related:   Angion Stock ...

2 months ago - Benzinga

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant pat...

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the phas...

2 months ago - Business Wire

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk f...

Angion to host a conference call at 4:30 p.m. EDT Angion to host a conference call at 4:30 p.m. EDT

2 months ago - GlobeNewsWire

Angion to Present Multiple Posters at Kidney Week 2021

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

2 months ago - GlobeNewsWire

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

4 months ago - GlobeNewsWire

Angion to Participate in Upcoming September Investment Conferences

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

4 months ago - GlobeNewsWire

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved drug ex...

5 months ago - Benzinga

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate P...

UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

5 months ago - GlobeNewsWire

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

6 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...

7 months ago - GlobeNewsWire

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associate...

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion's AKI-002-15 study,...

8 months ago - Business Wire

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated...

Topline data expected in the second half of 2021 Topline data expected in the second half of 2021

8 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

9 months ago - GlobeNewsWire

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated P...

Topline data expected in the first half of 2021 Topline data expected in the first half of 2021

9 months ago - GlobeNewsWire

Angion Announces Partial Waiver of Certain Lock-up Restrictions

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

9 months ago - GlobeNewsWire

Angion to Participate in Upcoming March Investment Conferences

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

10 months ago - GlobeNewsWire

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, In...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of n...

11 months ago - GlobeNewsWire

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of no...

11 months ago - GlobeNewsWire